Nautilus Biotechnology, Inc. reported results for the 2026 quarter in a 10-Q filing, generating $190K of revenue and posting a net loss of ($14.47M), or diluted EPS of ($0.11), modestly improved from the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$190K$0— | Net income²($14.47M)($15.03M)3.8% | Diluted EPS³($0.11)($0.12)8.3% |
¹ Reported as “Total revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable to common stockholders, basic and diluted”.
Business Highlights
- Revenue & Early Sales: Recognized grant revenue and began Early Access service sales in Q2 2026, producing modest, nonmaterial revenue from data services.
- Product development shift: Reallocated resources to accelerate targeted proteoform assays development, including Tau and AKT1.
- Commercialization timeline: Plans phased commercial launch with pre-orders targeted for early 2027 and instrument shipments starting mid-2027, initially with a limited assay set and expansion to blood samples.
- Go-to-market buildout: Initiated U.S. direct sales hires and intends to pursue direct U.S. sales with a mixed direct/distributor international strategy.
- Operational readiness: Focused on Early Access program scale-up, supply-chain readiness, and manufacturing plans for instruments, reagents and consumables.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.